Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Aug;108(8):940-949.
doi: 10.1007/s00392-019-01424-y. Epub 2019 Feb 14.

Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study

Affiliations
Multicenter Study

Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study

Prathap Kanagala et al. Clin Res Cardiol. 2019 Aug.

Abstract

Background: Proenkephalin (PENK), a stable endogenous opioid biomarker related to renal function, has prognostic utility in acute and chronic heart failure. We investigated the prognostic utility of PENK in heart failure with preserved ejection fraction (HFpEF), and its relationship to renal function, Body Mass Index (BMI), and imaging measures of diastolic dysfunction.

Methods: In this multicentre study, PENK was measured in 522 HFpEF patients (ejection fraction > 50%, 253 male, mean age 76.13 ± 10.73 years) and compared to 47 age and sex-matched controls. The primary endpoint was 2-years composite of all-cause mortality and/or heart failure rehospitalisation (HF). A subset (n = 163) received detailed imaging studies.

Results: PENK levels were raised in HFpEF (median [interquartile range] 88.9 [62.1-132.0]) compared to normal controls (56.3 [47.9-70.5]). PENK was correlated to urea, eGFR, Body Mass Index and E/e' (rs 0.635, - 0.741, - 0.275, 0.476, respectively, p < 0.0005). During 2 years follow-up 144 patients died and 220 had death/HF endpoints. Multivariable Cox regression models showed PENK independently predicted 2 year death/HF [hazard ratio (for 1 SD increment of log-transformed biomarker) HR 1.45 [95% CI 1.12-1.88, p = 0.005]], even after adjustment for troponin (HR 1.59 [1.14-2.20, p = 0.006]), and Body Mass Index (HR 1.63 [1.13-2.33, p = 0.009]). PENK showed no interaction with ejection fraction status for prediction of poor outcomes. Net reclassification analyses showed PENK significantly improved classification of death/HF outcomes for multivariable models containing natriuretic peptide, troponin and Body Mass Index (p < 0.05 for all).

Conclusions: In HFpEF, PENK levels are related to BMI, and measures of diastolic dysfunction and are prognostic for all-cause mortality and heart failure rehospitalisation.

Keywords: B-type natriuretic peptide; Heart failure; Opioids; Preserved ejection fraction; Proenkephalin; Renal function.

PubMed Disclaimer

Conflict of interest statement

Dr. Bergmann holds ownership in Sphingotec GmbH which manufactures the PENK assay, and is a member of the board of directors of Sphingotec GmbH. Dr. Struck is an employee of Sphingotec GmbH which manufactures the PENK assay. Dr. Mueller has received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the European Union, the Cardiovascular Research Foundation Basel, the University Hospital Basel, Abbott, Astra Zeneca, Beckman Coulter, BG medicine, Biomerieux, BRAHMS, Critical Diagnostics, Nanosphere, Roche, Siemens, Singulex, Sphingotec, 8sense as well as speaker/consulting honoraria from Abbott, Alere, Astra Zeneca, Biomerieux, BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Eli Lilly, Novartis, Roche, Sanofi, Siemens, and Singulex. Dr Squire has received research grants from Novartis AG and Servier as well as speaker/consulting honoraria from Novartis. The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
PENK relationship to the echocardiographic diastolic index E/e′. Correlation of PENK with echocardiographic index of diastolic dysfunction E/e′. The Spearman correlation coefficient was 0.453 (p < 0.0005)
Fig. 2
Fig. 2
MRI-derived ventricular volumes according to PENK tertiles. Box and whisker plots of a LAEDVI and b LAESVI according to PENK tertiles. LAEDVI and LAESVI differed between PENK tertiles (ANOVA p = 0.024 and 0.01). Significant differences were seen between the second and first tertile of LAEDVI (p = 0.025) and between second and third tertiles of LAESVI and the first tertile (p = 0.016 and 0.042, respectively)
Fig. 3
Fig. 3
Hazard ratios for PENK in Cox survival analysis for Death/HF or Death at 2 years in HFpEF and HFrEF. Forest plots showing hazard ratios and confidence intervals for PENK (as a univariable in A) following adjustment for a multivariable base model (B, containing the variables age, gender, NYHA class IV, past history of heart failure, ischemic heart disease, hypertension, diabetes, atrial fibrillation, systolic BP, heart rate, plasma urea, creatinine, sodium, haemoglobin, natriuretic peptide), base model with troponin (C), and base model with troponin and BMI (D). Hazard ratios for interaction of PENK with ejection fraction status are shown on the right of the figure
Fig. 4
Fig. 4
Kaplan–Meier survival analysis for death/HF hospitalisation and all-cause mortality. Kaplan–Meier plots of a the composite endpoint of death and/or HF hospitalization and b all-cause mortality, according to PENK tertiles. Log rank tests showed differences between tertiles 1 and 3 (p < 0.0005 for both endpoints), and between tertiles 2 and 3 (p = 0.006 for death/HF and p < 0.0005 for death)

Similar articles

Cited by

References

    1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–259. doi: 10.1056/NEJMoa052256. - DOI - PubMed
    1. Meta-analysis Global Group in Chronic Heart F The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750–1757. doi: 10.1093/eurheartj/ehr254. - DOI - PubMed
    1. Cheng JM, Akkerhuis KM, Battes LC, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. Eur J Heart Fail. 2013;15(12):1350–1362. doi: 10.1093/eurjhf/hft106. - DOI - PubMed
    1. Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011;4(5):569–577. doi: 10.1161/CIRCHEARTFAILURE.111.962654. - DOI - PubMed
    1. Tschöpe C, Birner C, Böhm M, et al. Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG) Clin Res Cardiol. 2018;107:1–19. doi: 10.1007/s00392-017-1170-6. - DOI - PubMed

Publication types

MeSH terms